Get the Stockscreener App
1.7806
0.00%
0.0006
Connect Biopharma Holdings Ltd Adr stock is traded at $1.7806, with a volume of 56,785.
It is up +0.00% in the last 24 hours and down -14.42% over the past month.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
See More
Previous Close:
$1.78
Open:
$1.78
24h Volume:
56,785
Relative Volume:
0.37
Market Cap:
$99.22M
Revenue:
-
Net Income/Loss:
$-21.38M
P/E Ratio:
-4.5656
EPS:
-0.39
Net Cash Flow:
$-25.19M
1W Performance:
+2.89%
1M Performance:
-14.42%
6M Performance:
+95.63%
1Y Performance:
+79.07%
1-Day Range:
$1.765
$1.83
1-Week Range:
$1.70
$1.92
52-Week Range:
$0.51
$2.86
Connect Biopharma Holdings Ltd Adr Stock (CNTB) Company Profile
Name
Connect Biopharma Holdings Ltd Adr
Sector
Industry
Phone
858-727-1040
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd Adr
|
1.7806 | 96.40M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.51 | 99.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.42 | 62.21B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.06 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
704.58 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
302.39 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Connect Biopharma Holdings Ltd Adr Stock (CNTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-12-25 | Initiated | H.C. Wainwright | Buy |
| Mar-04-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Apr-13-21 | Initiated | Piper Sandler | Overweight |
| Apr-13-21 | Initiated | SVB Leerink | Outperform |
Connect Biopharma Holdings Ltd Adr Stock (CNTB) Latest News
Connect Biopharma Advances Clinical Trials and Nasdaq Listing - AInvest
Connect Biopharma Posts Q2 Revenue Drop - AOL.com
Q3 Earnings Estimate for CNTB Issued By Leerink Partnrs - Defense World
HC Wainwright Cuts Earnings Estimates for Connect Biopharma - Defense World
Connect Biopharma Reports Q2 Revenue Drop of 99.2% to $48,000, R&D Spending Increases 65.6% to $8.8mln - AInvest
Connect Biopharma Holdings Ltd SEC 10-Q Report - TradingView
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Connect Biopharma Holdings Limited shares rise 5.63% after-hours following Jazz Pharmaceuticals' FDA approval of Modeyso. - AInvest
Connect Biopharma Shares Rise on Plan to End ADR Program and Directly List on Nasdaq - MSN
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Research Analysts Set Expectations for CNTB Q2 Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded at Northland Capmk - Defense World
Q2 Earnings Estimate for CNTB Issued By Northland Capmk - Defense World
Connect Biopharma stock rating reiterated as Outperform by Northland - Investing.com Australia
Connect Biopharma appoints Jim Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Connect Biopharma appoints Jim Schoeneck to board of directors - Investing.com Australia
Connect Biopharma appoints James A. Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Northland starts Connect Biopharma at Outperform on chance to define new class - TipRanks
Connect Biopharma stock rises after announcing plan to terminate ADR program - Investing.com
Connect Biopharma to terminate ADR program, list ordinary shares By Investing.com - Investing.com India
Connect Biopharma to terminate ADR program, list ordinary shares - Investing.com
Connect Biopharma to Terminate ADR Program and List Ordinary Shares on Nasdaq - Nasdaq
Connect Biopharma Announces Plans to Terminate its American - GlobeNewswire
Connect Biopharma Streamlines Trading: ADRs Convert to Direct Nasdaq Shares in Major US Market Push - Stock Titan
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewswire Inc.
Connect Biopharma regains Nasdaq compliance with minimum bid price rule - Investing.com India
Connect Biopharma regains Nasdaq compliance with minimum bid price rule By Investing.com - Investing.com South Africa
Connect Biopharma regains Nasdaq compliance with $1 minimum bid price - Investing.com
Connect Biopharma Holdings shares rise 7.89% in after-hours after partner's new drug application for atopic dermatitis is accepted by NMPA. - AInvest
Connect Biopharma’s partner submits new drug application in China - Investing.com
Connect Biopharma’s partner submits new drug application in China By Investing.com - Investing.com South Africa
Connect Biopharma (NASDAQ:CNTB) Trading Down 2.5% – Here’s What Happened - Defense World
Connect Biopharma reports positive data for asthma treatment By Investing.com - Investing.com South Africa
Connect Biopharma reports positive data for asthma treatment - Investing.com
Connect Biopharma begins Phase 2 asthma study - Investing.com
Connect Biopharma stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
Connect Biopharma stock hits 52-week low at $0.55 amid market challenges - Investing.com
FDA greenlights Connect Biopharma’s asthma and COPD trials - Investing.com
Connect Biopharma stock holds $8 target, Buy rating at H.C. Wainwright - Investing.com
Connect Biopharma faces Nasdaq delisting over share price By Investing.com - Investing.com India
Connect Biopharma faces Nasdaq delisting over share price - Investing.com
Connect Biopharma stock hits 52-week low at $0.76 - Investing.com
Connect Biopharma stock hits 52-week low at $0.91 amid market challenges - Investing.com
Connect Biopharma Holdings Ltd Adr Stock (CNTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):